Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Children ages 2 months to less than 19 years old, who have been diagnosed with a middle ear infection may receive either medicated ear drops (AR01) or glycerin (placebo) ear drops. The patient or caregiver will measure the amount of ear pain before and after the ear drops to establish if the medicated ear drops decrease the amount of pain more than the placebo ear drops. The subject may leave the clinic 60 minutes after the first dose. The ear drops can be used up to 4 days, as needed for ear pain.
The study involves the initial clinic visit, using the ear drops at home and keeping a diary about the ear pain experienced and medications taken. The patient will return to the clinic 4 days later for evaluation and to return the ear drops and diary. The clinic staff will call to follow-up about the patient's condition seven days after the initial visit.
Age
0 - 18 years
Sex
ALL
Healthy Volunteers
No
Clinical Research Consortium Arizona
Phoenix, Arizona, United States
Kern Allergy and Medical Research, Inc
Bakersfield, California, United States
Central California Research
Fresno, California, United States
Pharma Research International, Inc
Naples, Florida, United States
SCORE Physician Alliance, LLC
St. Petersburg, Florida, United States
Kentucky Pediatric / Adult Research
Bardstown, Kentucky, United States
Pioneer Clinical Research, LLC
Bellevue, Nebraska, United States
Omaha ENT Clinic
Omaha, Nebraska, United States
Children's Health Center / St. Elizabeth Medical Center
Utica, New York, United States
Valley Stream Pediatrics
Valley Stream, New York, United States
Start Date
December 1, 2013
Primary Completion Date
June 1, 2014
Completion Date
June 1, 2014
Last Updated
January 24, 2017
178
ACTUAL participants
AR01
DRUG
Placebo Comparator
DRUG
Lead Sponsor
Arbor Pharmaceuticals, Inc.
NCT05651633
NCT02591563
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02567825